Wikisage, the free encyclopedia of the second generation, is digital heritage
Drisapersen: Difference between revisions
Jump to navigation
Jump to search
m (→Links) |
mNo edit summary |
||
Line 6: | Line 6: | ||
[http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2019;volume=67;issue=3;spage=717;epage=723;aulast=Arora Duchenne muscular dystrophy: Still an incurable disease] | [http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2019;volume=67;issue=3;spage=717;epage=723;aulast=Arora Duchenne muscular dystrophy: Still an incurable disease] | ||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010191/ | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010191/ Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study] | ||
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study] | |||
{{refs}} | {{refs}} |
Revision as of 23:30, 11 September 2019
An exon skipping experimental Medicine[1] [2] PRO051/GSK2402968 is considered an orphan drug Duchenne muscular distrophy
Links
Duchenne muscular dystrophy: Still an incurable disease
References: |